KR20250049546A - Ip5 치환된 화합물 - Google Patents

Ip5 치환된 화합물 Download PDF

Info

Publication number
KR20250049546A
KR20250049546A KR1020257006598A KR20257006598A KR20250049546A KR 20250049546 A KR20250049546 A KR 20250049546A KR 1020257006598 A KR1020257006598 A KR 1020257006598A KR 20257006598 A KR20257006598 A KR 20257006598A KR 20250049546 A KR20250049546 A KR 20250049546A
Authority
KR
South Korea
Prior art keywords
compound
salt
inositol
myo
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257006598A
Other languages
English (en)
Korean (ko)
Inventor
카롤리나 살세도 로카
페레르 마리아 델 마르 페레즈
미구엘 데이비드 페레르 레이네스
모하마드 피라스 바시시
카르메 세라 코마스
후안 로렌조 카테나 루이즈
아마데오 레바리아 솔데빌라
호안 페렐로 베스타드
Original Assignee
사니핏 테라퓨틱스 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사니핏 테라퓨틱스 에스.에이. filed Critical 사니핏 테라퓨틱스 에스.에이.
Publication of KR20250049546A publication Critical patent/KR20250049546A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings with more than one hydroxy group bound to the ring
    • C07C35/16—Inositols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/188—Unsaturated ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020257006598A 2022-07-29 2023-07-31 Ip5 치환된 화합물 Pending KR20250049546A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22382737 2022-07-29
EP22382737.9 2022-07-29
PCT/EP2023/071141 WO2024023360A1 (en) 2022-07-29 2023-07-31 Ip5 substituted compounds

Publications (1)

Publication Number Publication Date
KR20250049546A true KR20250049546A (ko) 2025-04-11

Family

ID=83319363

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257006598A Pending KR20250049546A (ko) 2022-07-29 2023-07-31 Ip5 치환된 화합물

Country Status (11)

Country Link
EP (1) EP4562019A1 (enExample)
JP (1) JP2025525098A (enExample)
KR (1) KR20250049546A (enExample)
CN (1) CN119630679A (enExample)
AR (1) AR130072A1 (enExample)
AU (1) AU2023313051A1 (enExample)
CA (1) CA3263493A1 (enExample)
IL (1) IL318651A (enExample)
MX (1) MX2025001128A (enExample)
TW (1) TW202412815A (enExample)
WO (1) WO2024023360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162971A1 (en) * 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US7741506B2 (en) 2005-04-26 2010-06-22 Berry & Associates, Inc. Probe for measuring phytase activity
US20060241308A1 (en) * 2005-04-26 2006-10-26 Berry & Associates, Inc. Probe for measuring phytase activity
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US8987514B2 (en) * 2009-02-04 2015-03-24 President And Fellows Of Harvard College Compositions and methods for labeling and imaging phospholipids
GB0920985D0 (en) 2009-11-30 2010-01-13 Queen Mary & Westfield College Novel inositol phosphate derivatives
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
SMT202100406T1 (it) 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica
EP3852767B1 (en) 2018-09-18 2025-12-17 Vifor (International) AG Calcium oxalate crystallization inhibitors for renal disorders
WO2021219135A1 (zh) 2020-04-30 2021-11-04 上海森辉医药有限公司 一种肌醇衍生物及其用途
EP4036097A1 (en) * 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds

Also Published As

Publication number Publication date
EP4562019A1 (en) 2025-06-04
MX2025001128A (es) 2025-03-07
TW202412815A (zh) 2024-04-01
CN119630679A (zh) 2025-03-14
CA3263493A1 (en) 2024-02-01
AR130072A1 (es) 2024-10-30
JP2025525098A (ja) 2025-08-01
IL318651A (en) 2025-03-01
WO2024023360A1 (en) 2024-02-01
AU2023313051A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
EP2419430A2 (en) Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
EP2834234B1 (en) Fused cyclopentyl antagonists of ccr2
EP3613420B1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
US12612365B2 (en) Compounds and methods for treating alcohol disorder
US20240109924A1 (en) Ip4-4,6 substituted derivative compounds
AU2023313051A1 (en) Ip5 substituted compounds
EP4056570B1 (en) Eed inhibitor, and preparation method therefor and use thereof
WO2012150866A1 (en) Phosphoribosyltransferase inhibitors and uses thereof
WO2024023359A1 (en) Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
FI90982B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten mitomysiinifosfaattijohdannaisten valmistamiseksi
WO2018022529A1 (en) Pantetheine derivatives for the treatment of neurologic disorders
WO2025162971A1 (en) Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
EA050725B1 (ru) Замещенные производные соединений ip4-4,6
EP1847270B1 (en) Use of amygdalin analogues for the treatment of psoriasis
EP4700015A1 (en) Heterocyclic ring-substituted aromatic compound, preparation method therefor, and use thereof
HK40072387A (en) Eed inhibitor, and preparation method therefor and use thereof
HK40094155A (en) Ip4-4,6 substituted derivative compounds
EP4647434A1 (en) Modulator for promoting binding of butyrophilin 3a1/2a1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application